Antihistamine Switch Label Comprehension Studies Not Needed, FDA Says
This article was originally published in The Tan Sheet
Executive Summary
Label comprehension and actual use studies are not necessary for switching second-generation, Rx antihistamines OTC, FDA Division of Pulmonary & Allergy Drugs Director Robert Meyer, MD, said May 11.
You may also be interested in...
OTC Claritin Hatch/Waxman Exclusivity Not Expected By Schering-Plough
Schering-Plough does not expect to receive three years of Hatch/Waxman exclusivity for its supplemental NDAs for OTC Claritin (loratadine)
OTC Claritin Hatch/Waxman Exclusivity Not Expected By Schering-Plough
Schering-Plough does not expect to receive three years of Hatch/Waxman exclusivity for its supplemental NDAs for OTC Claritin (loratadine)
OTC Claritin Hatch/Waxman Exclusivity Not Expected By Schering-Plough
Schering-Plough does not expect to receive three years of Hatch/Waxman exclusivity for its supplemental NDAs for OTC Claritin (loratadine)